Literature DB >> 2705536

Anion dependence of taurine transport by rat renal brush-border membrane vesicles.

I Zelikovic1, E Stejskal-Lorenz, P Lohstroh, A Budreau, R W Chesney.   

Abstract

The anionic requirements and the stoichiometric relationships of Na+-taurine cotransport into rat renal brush-border membrane vesicles (BBMV) were evaluated. External Cl- (100 mM) or Br- (100 mM) gradients supported the full overshoot of Na+-taurine symport and yielded similar high-affinity transport systems for taurine uptake. No active uptake of taurine was evident in the presence of external (100 mM) NaF, NaI, Na gluconate, or Na p-aminohippurate (PAH). Na+:taurine stoichiometry was 2.18:1 in the presence of Cl- and 1.60:1 in the presence of Br-. When the external anion gluconate was employed, Na+-dependent taurine uptake was negligible over the whole range of Na+ concentrations examined. Cl-:taurine and Br-:taurine stoichiometries in the presence of external Na+ were 0.97:1 and 0.81:1, respectively. External furosemide (1 mM) or bumetanide (1 mM) did not change taurine accumulation and kinetic parameters. The anionic transport inhibitors 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (5 x 10(-4) M), N-(4-azido-2-nitrophenyl)-2-aminoethylsulfonate (10(-3) M) and p-chloromercuribenzoate (5 x 10(-4) M) significantly decreased initial rate of taurine uptake by 48, 31, and 31%, respectively. These data suggest that Na+-taurine cotransport into rat renal BBMV is Cl- or Br- dependent and probably operates by means of 2 Na+:1 Cl- or Br-:1 taurine carrier complex. Na+-taurine symport across the rat renal brush-border membrane surface is not affected by diuretics that influence NaCl cotransport but is affected by selected anionic transport inhibitors. An intact anionic binding site may be needed for this translocation process.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2705536     DOI: 10.1152/ajprenal.1989.256.4.F646

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  The gamma-aminobutyric acid transporter and its interaction with taurine in the apical membrane of the bovine retinal pigment epithelium.

Authors:  S Sivakami; V Ganapathy; F H Leibach; Y Miyamoto
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

2.  Taurine: A therapeutic agent in experimental kidney disease.

Authors:  H Trachtman; J A Sturman
Journal:  Amino Acids       Date:  1996-03       Impact factor: 3.520

Review 3.  The renal transport of taurine and the regulation of renal sodium-chloride-dependent transporter activity.

Authors:  R W Chesney; I Zelikovic; D P Jones; A Budreau; K Jolly
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

4.  Sodium-taurine cotransport in reptilian renal brush-border membrane vesicles.

Authors:  S Benyajati; S M Bay
Journal:  Pflugers Arch       Date:  1992-06       Impact factor: 3.657

Review 5.  Taurine and the renal system.

Authors:  Russell W Chesney; Xiaobin Han; Andrea B Patters
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

6.  Polarized nature of taurine transport in LLC-PK1 and MDCK cells: Further characterization of divergent transport models.

Authors:  D P Jones; R W Chesney
Journal:  Amino Acids       Date:  1993-10       Impact factor: 3.520

Review 7.  The role of protein phosphorylation in renal amino acid transport.

Authors:  I Zelikovic; J Przekwas
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

Review 8.  Renal amino acid transport: cellular and molecular events from clearance studies to frog eggs.

Authors:  R W Chesney; D Jones; I Zelikovic
Journal:  Pediatr Nephrol       Date:  1993-10       Impact factor: 3.714

9.  Efflux of taurine from renal brush border membrane vesicles: is it adaptively regulated?

Authors:  R W Chesney; A M Budreau
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

10.  Taurine behaves as an osmolyte in Madin-Darby canine kidney cells. Protection by polarized, regulated transport of taurine.

Authors:  S Uchida; T Nakanishi; H M Kwon; A S Preston; J S Handler
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.